Plain-English translation of NCT07037433 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called to see if it can reduce the risk of serious heart and blood vessel problems in people who have already had a heart attack, stroke, or circulation issues and are overweight or living with obesity. About 12,800 people will be enrolled worldwide. Half will receive the new medication as a weekly injection, and half will receive a placebo injection, while both groups continue their regular heart care.
People who have survived a heart attack or stroke remain at high risk for future cardiovascular events, even with standard treatment. This trial aims to find out whether this medication can provide additional protection beyond what current treatments offer.
You likely qualify if…
You likely don't qualify if…
You will receive either the new medication or a placebo as a weekly injection under the skin, along with your regular heart care. You'll attend regular clinic visits for check-ups, blood tests, and monitoring of your heart health. The study will follow you for an extended period to see whether the medication reduces your risk of future heart attacks, strokes, or other serious cardiovascular events.
AI-generated summary from trial data · Jul 14, 2026 · Not medical advice
United States